Human adipose-derived mesenchymal stem cells for osteoarthritis: a pilot study with long-term follow-up and repeated injections. (8th February 2018)

• Record Type: Journal Article
• Authors: Song, Yang; Du, Hui; Dai, Chengxiang; Zhang, Li; Li, Suke; Hunter, David J; Lu, Liangjing; Bao, Chunde
• Is Part Of: Regenerative medicine. Volume 13:Number 3(2018)
• Page Start: 295
• Page End: 307
• Publication Date: 2018-02-08
• Subjects: cartilage -- cell therapy -- clinical trials -- function -- intra-articular -- mesenchymal stem cells -- MRI -- MSC -- osteoarthritis -- pain; Cellular therapy -- Periodicals; Stem cells -- Transplantation -- Periodicals; Degeneration (Pathology) -- Treatment -- Periodicals; Regeneration (Biology) -- Periodicals; 611.018
• DOI: 10.2217/rme-2017-0152
• Languages: English
• ISSNs: 1746-0751

Abstract

Aim: This study aimed to evaluate the safety and therapeutic potential of autologous human adipose-derived mesenchymal stem cells (haMSCs) in patients with osteoarthritis.Materials & methods: Safety and efficacy of haMSCs were preclinically assessed in vitro and in BALB/c-nu nude mice. 18 patients were enrolled and divided into three dose groups: the low-dose, mid-dose and high-dose group (1 × 10 7, 2 × 10 7 and 5 × 10 7 cells, respectively), provided three injections and followed up for 96 weeks.Results & Conclusion: The preclinical study established the safety and efficacy of haMSCs. Intra-articular injections of haMSCs were safe and improved pain, function and cartilage volume of the knee joint, rendering them a promising novel treatment for knee osteoarthritis. The dosage of 5 × 10 7 haMSCs exhibited the highest improvement (ClinicalTrials.gov Identifier: NCT01809769).